Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of ALE.C04 in Patients With Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
- Status
- RECRUITING
- Phase
- PHASE2
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
- Status
- RECRUITING
- Phase
- PHASE2
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Status
- COMPLETED
- Phase
- PHASE2
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1